Date | Price Target | Rating | Analyst |
---|---|---|---|
9/7/2023 | $4.00 | Buy | B. Riley Securities |
10/14/2021 | $10.00 | Buy | B. Riley Securities |
4 - Cytosorbents Corp (0001175151) (Issuer)
4 - Cytosorbents Corp (0001175151) (Issuer)
4 - Cytosorbents Corp (0001175151) (Issuer)
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J. Mariani as Chief Financial Officer (CFO), effective August 14, 2024. Mr. Mariani will report to Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. Concurrently, Kathleen P. Bloch, CytoSorbents' current CFO, announced her retirement from the Company effective as of the close of business today, and will continue to serve in an advisory role as a consultant to enable an effective t
PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the re-appointment of Kathleen P. Bloch as full-time Chief Financial Officer, effective retroactively to September 2, 2023. Ms. Bloch served as the Company's Chief Financial Officer for 10 years until her retirement in March 2023, when she became Interim CFO as a consultant. She resumed as Interim CFO after the investigation of, and mutual termination and release agreement with, former CFO
PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that Alexander D'Amico has resigned as the Company's Chief Financial Officer as part of a mutual termination and release agreement with the Company, effective August 28, 2023. As part of the agreement, CytoSorbents and Mr. D'Amico have agreed to terminate his employment agreement with the Company dated July 10, 2023 in its entirety, and have agreed to customary and mutual non-disparagement and release provisions, payment
B. Riley Securities initiated coverage of CytoSorbents with a rating of Buy and set a new price target of $4.00
B. Riley Securities resumed coverage of CytoSorbents with a rating of Buy and set a new price target of $10.00
8-K - Cytosorbents Corp (0001175151) (Filer)
S-8 - Cytosorbents Corp (0001175151) (Filer)
8-K - Cytosorbents Corp (0001175151) (Filer)
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that the Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY. A company presentation will be available on demand here as of Monday, September 9 at 7:00 AM ET. CytoSorbents' management team wi
PRINCETON, N.J., Aug. 16, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that it granted inducement equity awards on August 14, 2024 (the "Grant Date") to its newly-hired Chief Financial Officer, Peter J. Mariani. The inducement equity awards consist of (i) a non-qualified stock option to purchase 215,000 shares of CytoSorbents' common stock ("Common Stock"), which vest upon the achievement of certain performance milestones described in Mr. Mariani's employment agreement, (ii)
New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarterIn Q2 2024, increased product sales by 10% and reduced operating loss by 48%Achieved more than a quarter million CytoSorb treatments cumulatively delivered to date – a major company milestone PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Results Total revenue for Q2 202
4 - Cytosorbents Corp (0001175151) (Issuer)
3 - Cytosorbents Corp (0001175151) (Issuer)
4 - Cytosorbents Corp (0001175151) (Issuer)
CytoSorbents Corp (NASDAQ:CTSO) shares are trading higher by 21% to $0.85 during Tuesday’s session after the company entered into a new $20 million credit facility with Avenue Capital Group. The company says the funds will provide non-dilutive working capital to support the global CytoSorb® franchise in critical care and cardiac surgery, and aid in FDA and Health Canada applications for DrugSorb™-ATR. The credit agreement has a three-year term and includes an initial $15 million tranche, with $10 million available immediately and an additional $5 million contingent on FDA acceptance of the DrugSorb-ATR De Novo application. Meanwhile, a second $5 million tranche is available in lat
Proceeds from the facility are intended to provide non-dilutive working capital to support the Company's ongoing global CytoSorb® franchise in critical care and cardiac surgery that generated $32.2 million in trailing 12-month sales as of March 31, 2024, planned marketing applications to U.S. Food and Drug Administration (FDA) and Health Canada for DrugSorb™-ATR and initial launch and commercialization preparations if approved, and refinancing of existing Bridge Bank debt.
New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarterIn Q2 2024, increased product sales by 10% and reduced operating loss by 48%Achieved more than a quarter million CytoSorb treatments cumulatively delivered to date – a major company milestone PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Results Total revenue for Q2 202
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2024 operating and financial results after the market close on Tuesday, August 13, 2024. CytoSorbents' management will host a live conference call, presentation webcast, and a question and answer session starting at 4:30PM EDT the same day. Webcast Details:Date: Tuesday, August 13, 2024Time: 4:30 PM EDTLive webcast link: https://edge.media-server.com/mmc/p/smuwcy9aConference ID: 7567925 Participant Dial-In:Participant Dial-in toll-free:
Product Sales up a robust 14% over prior year, and a significant 22% sequentiallyWe believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients On track for U.S. Food and Drug Administration (FDA) De Novo and Health Canada submissions for DrugSorb®-ATR in Q3 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended March 31, 2024. The Company reported a robust 14% increase in product sales year over year and
SC 13G - Cytosorbents Corp (0001175151) (Subject)
SC 13G - Cytosorbents Corp (0001175151) (Subject)
SC 13G - Cytosorbents Corp (0001175151) (Subject)